Bis-anthracyclines with high activity against doxorubicin resist

Details Bis-anthracyclines with high activity against doxorubicin resist Bis-anthracyclines with high activity against doxorubicin resist

1997-03-21

1999-02-23

Peselev, Elli

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 64, 552201, A61K 3170, C07H 1708

Patent

active

058744126

ABSTRACT:
The present invention discloses new and novel bisanthracyclines linked through the saccharide portions. These compounds show high activity against two clinically relevant mechanisms of resistance. A novel approach of the invention produces compounds that are as active or more so than the parent compounds. Furthermore, the inventor's discovery is also for the design of effective DNA-binding bisanthracyclines as well as anthracyclines mixed with other intercalators and groove binders.

REFERENCES:
patent: 4112217 (1978-09-01), Henry et al.
patent: 4263428 (1981-04-01), Apple et al.
patent: 4749693 (1988-06-01), Anzelucci et al.
patent: 5132290 (1992-07-01), Priebe et al.
Arcamone F., "Doxorubicin," Anti-Cancer Antibiotics. New York: American Press, 1981.
Bell et al., "Detection of P-Glycoprotein in Ovarian Cancer: A Molecular Marker Associated With Multidrug Resistance," J. Clin. Oncol., 3:311, 1985.
Bertino, "The Multidrug Resistance Phenotype," J. Clin. Oncol., 3(5):293, 1985.
Bodley et al., "DNA Topoisomerase II-Mediated Interaction of Doxorubicin and Daunorubicin Congeners with DNA.sup.1," Cancer Res., 49:5969-5978, 1989.
Booser D.J. and Hortobgyi G.N., "Anthracycline Antibiotics in Cancer Therapy. Focus on Drug Resistance," Drugs, 47(2):223-258, 1994.
Bradley et al., "Mechanism of Multidrug Resistance," Biochem. Biophys. Acta., 948:87-128, 1988.
Brandts and Lin, "Study of Strong to Ultralight Protein Interactions Using Differenctial Scanning Calorimetry," Biochemistry, 29:6927-6940, 1990.
Capranico et al., "Sequence-Selective Topoisomerase II Inhibition by Anthracycline Derivatives in SV40 DNA: Relationship with DNA Binding Affinity and Cytotoxicity," Biochem., 29:562-569, 1990.
Chaires et al., "A New Generation of Bisintercalating Anthracycline Antibiotics," Abstract 017 Presented at the ACS meeting, Mar. 15, 1996.
Chaires et al., "Structure-Based Design of a New Bisintercalating Anthrecycline Antibiotic," Journal of Medicinal Chemistry, 40(3):261-266, 1997.
Chaires J.B., "Application of Equilibrium Binding Methods to Elucidate: The Sequence Specificity of Antibiotic Binding to DNA," Hurley L.H., Ed., Advances in DNA Sequence Specific Agents., 1: Jai Press, 1991.
Chaires J.B., "Biophysical Chemistry of Daunomycin-DNA Interaction," Biophys. Chem., 35:191-202, 1990.
Chaires J.B., Herrera J.E., and Waring M.J., "Preferential Binding of Daunomycin to 5' .sub.T.sup.A CG and 5' .sub.T.sup.A GC Sequences Revealed by Footprinting Titration Experiments,"Biochemistry, 29:6145-6153, 1990.
Chaires, J.B., "Daunomycin Binding to DNA: From the Macroscopic to the Microscopic," Eds. Pullman B. and Jortner J., Molecular Basis of Specificity in Nucleic Acid-Drug Interactions: Kluwer Academic Publishers, 123-126, 1990.
Cohen and Eisenberg, "Viscosity and Sedimentation Study of Sonicated DNA-Proflavine Complexes*," Biopolymers, 8:45-55, 1969.
Cornbleet et al., "Mitoxantrone for the Treatment of Advanced Breast Cancer: Single-Agent Therapy in Previoulsy Untreated Patients," Eur. J. Cancer Clin. Oncol., 20(9):1141-1146, 1984.
Crothers D.M., "Statistical Thermodynamics of Nucleic Acid Melting Transitions with Coupled Binding Equilibria," Biopolymers, 10:2147-2160, 1971.
Curt et al., "Drug Resistance in Cancer," Cancer Treat. Rep., 68:87, 1984.
Danks et al., Atypical Multiple Drug Resistance in a Human Leukemic Cell Line Selected for Resistance to Teniposide (VM-26).sup.1 Cancer Res., 47:1297-1301, 1987.
Dawson K.M., "Activity of SC33428, A Novel Bis-Hydrozone Bridged Derivative of 4-Demethoxydaunomycin, Against Experimental Tumors in Mice," Cancer Res., 43:2880-2883, 1983.
Denny et al., "Potential Anti-Tumor Agents. 39. Anilino Ring Geomentry of Amsacrine and Derivatives: Relationship to DNA Binding and Anti-Tumor Activity," J. Med. Chem., 26(11):1625-1630, 1983.
Dervan P., "Design of Sequence-Specific DNA-Binding Molecules," Science, 232:464-471, 1986.
Dowd, Editor, "The Physicians Desk References," Medical Economics Company Inc., Oradell, N.J., 1990.
Fojo et al., "Expression of a Multidrug-Resistance Gene in Human Tumors," P.N.A.S., 84:265-269, 1987.
Gallois et al., "The Overall Partitioning of Anthracyclines into Phosphatidyl-Containing Model Membranes Depend Neither on the Drug Charge Nor on the Presence of Anionic Phospholipids," Abstract 051 Presented at the ACS meeting, Mar. 15, 1996.
Ganapathi, et al., "N-Benzyladriamycin-14-Valerate Versus Progressively Doxorubicin-Resistant Murine Tumors: Cellular Pharmacology and Characterization of Cross-Resistance In Vitro and In Vivo,"Br. J. Cancer, 60:819-826, 1989.
Gennaro, A.R., Editor, "Remington's Pharmaceutical Sciences,"Mack Publishing Company, Easton, Pennsylvania, 1990.
Goldie et al., "A Mathematic Model for Relating the Drug Sensitivity of Tumors to Their Spontaneous Mutation Rate .sup.1," Cancer Treat. Rep., 63(11-12):1727-1731, 1979.
Goldie et al., "The Genetic Origin of Drug Resistance in Neoplasmas: Implications for Systemic therapy," Cancer Res., 44:3643-3653, 1984.
Green, Reade, and Ware, "Rapid Colormetric Assay for Cell Viability: Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines," J. Immunol. Methods, 70:257-268, 1984.
Gros et al., "Isolation and Expression of a Complementary DNA that Confers Multidrug Resistance," Nature, 323:728-731, 1986.
Hsiang et al., "Topoisomerase II-Mediated DNA Cleavage by Amonafide and Its Structural Analogs," Mol. Pharmacol., 36(3):371-376, 1989.
Israel et al., "Comparative Uptake and Retention of Adriamycin and N-Benzyladriamycin-14-Valerate in Human CEM Leukemic Lymphocyte Cell Cultures," Cancer Chemother. Pharmacol., 25:177-183, 1989.
Israel et al., "Comparative Effects of Adriamycin and DNA-Non-Binding Analogues on DNA, RNA, and Protein Synthesis in Vitro," Cancer Chemother. Pharmacol., 20:277-284, 1987.
Katsumata et al., "Prevention of Breast Tumor Development In Vivo by Down-Regulation of the p185.sup.neu Receptor", Nature Med., 1(7):644-648, 1995.
Kolata, "Why Do Cancer Cells Resist Drugs?" Science, 231:220-221, 1986.
Kopka et al., "Binding of An Antitumor Drug to DNA Netropsin and C-G-C-G-A-A-T-T.sup.BR C-C-G-C-G", J. Mol. Biol., 183:553-563, 1985.
Krawczyk et al., "Synthesis and Cytotoxic Properties of 14-0-Acylated Hydroxyrubicins," Abstract 048 Presented at the ACS meeting, Mar. 15, 1996.
Lampidis et al., "Lipophilicity and Positive Charge Influence Selectivity and Localization of Anthracyclines in P-GP Mediated Multidrug Resistant and Sensitive Cell Types," Abstract 027 Presented at the ACS meeting, Mar. 15, 1996.
Lothstein et al., "Anthracycline Metabolism and Its Therapeutic Potential," Abstract 030 Presented at the ACS meeting, Mar. 15, 1996.
Lown JW, "Targeting the DNA Minor Groove for Control of Biological Function: Progress, Challenges and Prospects", Chemtracts --Org. Chem., 6:205-237, 1903.
Lown JW., "Anthracycline and Anthracenedione-Based Anticancer Agents. Bioactive Molecules," 6: Amsterdam: Elsevier, 1988.
McGhee JD, "Theoretical Calculations of the Halix-Coil Transition of DNA in the Presence of Large, Cooperatively Binding Ligands", Biopolymers, 15:1345-1375, 1976.
Moscow et al., "Multidrug Resistance," Journal of the National Cancer Institute, 80(1):14-20, 1988.
Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay", J. Immunol. Methods, 65:55-63, 1983.
Mrksich et al., "Antiparallel Side-by-Side Dimeric Motif for Sequence-Specific Recognition in the Minor Groove of DNA by the Designed Peptide 1-Methylimidazole-2-Carboxamide Netropsin", Proc. Nat'l. Acad. Sci. U.S.A., 89:7586-7590, 1992.
Norris et al., "Expression of the Gene for Multidrug-Resistance-Associated Protein and Outcome in Patients with neuroblastoma," N. Engl. J. Med., 334:231-238, 1996.
Nowell, "Mechanisms of Tumor Progression," Cancer Res., 46:2203-2207, 1986.
Pelton and Wemmer, Structural Characterization of a 2:1 Distamycin A-d(CGCAAATTGGC) Complex by Two-Dimensional NMR, Proc. Nat'l. Acad. Sci. U.S.A., 86:5723-5727, 1989.
Perez-Soler et al., "Development of Liposomal-Annamycin," Abstract 035 Presented at the ACS meet

Affiliated with

Also associated with

Rating

Bis-anthracyclines with high activity against doxorubicin resist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bis-anthracyclines with high activity against doxorubicin resist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bis-anthracyclines with high activity against doxorubicin resist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-307004